April 4, 2025 8:21am
A lot of blood on the cell and gene sector’s street, help clean it up!
There’s always market volatility related to inflation oriented econs … here now then it will be gone
News: Mesoblast (MESO -$0.55 pre-open) the status of its products in relation to the U.S. Government’s announcement on tariffs for imported products. MESO believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will NOT be subject to the tariffs. Sangamo Therapeutics (SGMO +$0.14 pre-open) has entered into a license agreement with Eli Lilly (LLY) allowing Lilly to leverage SGMO’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. <continued ($) below>
Breaking: U.S. payrolls, job growth was stronger than expected in March, providing at least temporary reassurance that the labor market is stable, the Labor Department reported. Nonfarm payrolls increased 228,000 for the month, up from the revised 117,000 in February and better than the estimate for 140,000, according to the Bureau of Labor Statistics. However, the unemployment rate moved up to 4.2%, higher than the 4.1% forecast.
Pre-open Indications: 4 Negative Indications
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
I am NOT often wrong and always consider doubt of some market and sector share pricing movements
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Thursday’s RegMed Investors’ (RMi) pre-open: when markets get wasted … https://www.regmedinvestors.com/articles/13865
Thursday’s night’s … RegMed Investors (RMi) Closing Bell: although early, snorkel for bottom values … https://www.regmedinvestors.com/articles/13866
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812
News (continued): The SGMO and LLY agreement grants LLY a worldwide exclusive license to utilize the STAC-BBB capsid for one initial target, with the right to add up to 4 additional targets after paying additional licensed target fees, to deliver their intravenously administered genomic medicines to treat certain diseases of the central nervous system. Under the terms of the agreement, Sangamo is responsible for completing a technology transfer related to the STAC-BBB capsid. Lilly is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of any resulting gene therapy products. Sangamo will receive an $18 million upfront license fee from Lilly and is eligible to earn up to $1.4 B in additional licensed target fees and milestone payments across the five potential neurology disease targets, as well as tiered royalties on potential net sales of such products, subject to certain specified reductions.
Friday: The pre-open Dow futures are DOWN -3.15% or (-1,285 points), the S&P futures DOWN -3.12% or (-171 points) and the Nasdaq futures are DOWN -3.34% or (-623 points)
- U. S. futures take more of a pounding, Friday, 4/4 as China will impose a 34% levy on all U.S. products,
- European stock markets continued to tumble,
- Asia Pacific markets stumble
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Thursday: The Dow closed DOWN -1,656.28 points or -3.92%, the S&P closed DOWN -274.45 points or -4.84% while the Nasdaq closed DOWN -1,050.44 points or -5.97%
The week so far, the Nasdaq is down -5.5%, the S&P -3.3% while the Dow has slid 2.5%. Both the Nasdaq and S&P 500 are tracking for their worst weekly performances since September 2024 and 6th negative week of the last 7.
Economic Data Docket: jobs report for March.
- Economists expect nonfarm payrolls to rise by 140,000 jobs and the unemployment rate to hold steady at 4.1%.
Q2- April – 2 negative and 1 positive closes
- Q1/25 – March, 10 positive and 11 negative closes
- February – 12 holiday, 11 negative and 7 positive closes
- January - 2 holidays, 1 market close, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
- Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the … econs, it is still a mix of ups, downs and just uncertainty
Although …
Negative Indications:
Alnylam Pharmaceuticals (ALNY) closed down -$4.46 after Wednesday’s +$11.07 after Tuesday’s -$14.26 after Monday’s +$1.46 with a negative -$19.81 or -7.56% pre-market
AxoGen (AXGN) closed down -$0.65 after Wednesday’s-$0.12 after Tuesday’s -$0.69 after Monday’s +$0.15 with a negative -$0.65 or -1.04% pre-market
Sage Therapeutics (SAGE) closed down -$0.40 with a negative -0.22 or -2.99% pre-market
Intellia Therapeutics (NTLA) closed down -$0.41 with a negative -$0.32 or -4.64% pre-market
The BOTTOM LINE: Maintaining, “I think speculative behavior in this current market has ascended to a level beyond common sense.”
Merger and acquisition (M&A) activity; sector companies will seek opportunities to sell to better financed companies that can "deal with these additional costs associated of R&D and escalating SG&A.”
NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”
What could 2025 have in store for the capital access space as Partners are the gift of life!
- "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
